JPRN-UMIN000013038已完成未知
Analysis of pharmacokinetics and pharmacodynamics for capecitabine during new chemotherapy regimen by bevacizumab (Bev) in combination with XELOX in unresectable colorectal cancer - Analysis of pharmacokinetics and pharmacodynamics for Capecitabine during new chemotherapy regimen
Tsukasa Hotta0 个研究点目标入组 10 人开始时间: 2014年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Treatment for ascites and thoracic effusion is needed. 2.There is brain tumor or brain metastasis. 3.Untreated double cancer within 5 years 4.There is cerebrovascular disease 5.surgery within 4 weeks 6.surgery for study 7.use of drug effected for blood coagulation system 8.Bleeding tendency 9.Uncontrorable peptic ulcer 10.gastrointestinal perforation within 6 months 11.untreated fructure 12.renal failure 13.Uncontrorable hypertension 14.Uncontrorable diabetes meritus 15.heart disease 16.hypersensitivity for fluorouracil and platinum 17.DPD defect 18.Uncontrorable diarrhea 19.interstitial pneumonia or pulmonary fibrosis 20.organ transplant needed immunosuppressant drug 21.Uncontrorable infectious disease 22.similarterm for BV treatment 23.difficult for oral intake
研究者
相似试验
尚未招募
不适用
A study on the pharmacokinetics and pharmacodynamics of remimazolam during total intravenous anesthesia with remifentanilKCT0007066Inje University Busan Paik Hospital15
进行中（未招募）
1 期
study of the pharmacokinetics and pharmacodynamics of desmopressin oral lyophilisate - route of administration in the pediatric patient population - SAFEPEDRUGEUCTR2014-005200-13-BEGhent University24
招募中
不适用
Pharmacokinetic, pharmacodynamic and pharmacogenetic research on biomarkers in cancer patients with special response to pharmacological therapyMalignancyJPRN-UMIN000011798Medical Oncology / Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine600
已完成
不适用
Assessment of pharmacokinetics and pharmacokinetic drug-drug interaction with ketoconazole of the metabolite S 41015 after single oral unlabelled microdoses of S 41015 and i.v. radiolabelled microdoses of [14C]-S 41015, and pharmacokinetics of S 38844 after single oral unlabelled microdose of S 38844 and i.v. radiolabelled microdose of [14C]-S 38844 in healthy male participantshart- en vaatziektencardiovascular diseasesNL-OMON38625Institut de Recherches Internationales Servier I.R.I.S6
进行中（未招募）
不适用
A Study of the Pharmacodynamics, Pharmacokinetics, and Safety & Efficacy of ARC1779 Injection in Patients with von Willebrand Disease Type 2B - ARC1779 for VWD-2Bvon Willebrand Disease type 2BEUCTR2008-008532-82-ATMedical University of Vienna, Dept. of Clinical Pharmacology